Mustafa Duran

Dr. Mustafa Duran


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Cancer Management and Research
Verified
Journal Article
Open access
MDMustafa Duran
Mustafa Duran
KEKAĞA ELİF
KAĞA ELİF
Objective: Myeloid leukemia is a stem cell disease with high mortality due to the challenges of high-dose treatments and side effects. Innovative nanoparticle drug delivery systems are being explored to enhance efficacy and tissue-targeted therapy. This study investigates the potential of Bentonite (BNT)-based nanoparticles (NPs) as drug carriers for azacitidine (AZA) in treating THP-1 and K562 myeloid leukemia (AML) cell lines, aiming to improve drug stability, bioavailability, and therapeutic efficacy while ensuring controlled release. Material and Method: Bentonite clay morphology was analyzed using Scanning Electron Microscopes. The BNT-AZA combination was tested in THP-1 and K562 cell cultures via in vitro proliferation tests, CCK-8 assays, and drug release tests with dialysis membranes. Apoptosis and internalization were evaluated using Annexin V-FITC and fluorescence methods, respectively. Results: The BNT-AZA exhibited controlled release over 8 hours, with 50% released within 2 hours, 90% by the 4th hour, and prolonged release beyond 8 hours. This profile reduces side effects while increasing efficacy in target cells. Bentonite demonstrated significant drug-loading capacity, controlled release, and tumor-targeting capabilities. At concentrations of 10, 25, 50, and 100 mu g/mL, BNT showed dose-dependent antiproliferative effects, maintaining low cytotoxicity at lower concentrations. The combination of azacytidine and bentonite exhibited a synergistic effect in inhibiting cell proliferation, with significant decreases in cell viability in the 1 mu M azacytidine + 10 mu g/mL bentonite, 5 mu M azacytidine + 10 mu g/mL bentonite, and 10 mu M azacytidine + 10 mu g/mL bentonite groups compared to the controls. The combination of 1 mu M AZA with 10 mu g/mL BNT achieved similar efficacy to 10 mu M AZA alone, suggesting a potential for dose reduction and improved safety. Conclusion: BNT nanoparticles are promising carriers for AZA, enhancing targeted delivery, reducing side effects, and potentially lowering the required dose for leukemia treatment. These findings support further investigation into the clinical application of BNTAZA in hematologic cancers.

9 April 2023 in Health Sciences Quarterly
Verified
Journal Article
Open access
PDF file
ASAlper Sari
Alper Sari
HGHaydar Güngören
Haydar Güngören
EKElif Dizen Kazan
Elif Dizen Kazan
SOSemiha Orhan
Semiha Orhan
MDMustafa Duran
Mustafa Duran
EBErhan Bozkurt
Erhan Bozkurt
In this study, we aimed to evaluate the effect of monocyte/high-density lipoprotein (MHR), which is associated with systemic inflammation: on prolonged hospitalization in patients with mild acute pancreatitis. Patients hospitalized for acute edematous pancreatitis between 01.01.2021 and 31.12.2021 were retrospectively screened. Arrival Ranson scores of the patients were calculated. Those with a Ranson score <3 were considered as mild acute pancreatitis and were included in the study. Patients with mild acute pancreatitis were divided into 2 groups with a hospital stay of <8 days and ≥8 days. Monocyte/HDL, biochemical and metabolic parameters were compared between the groups. The study was conducted with a total of 39 patients, 23 male (59%) and 16 female (41%). While 28 (71.8%) of the patients were discharged within <8 days, 11 (28.2%) were hospitalized for ≥8 days. Group ≥8 days was considered as prolonged hospitalization. It was determined that the monocyte/HDL ratio was significantly higher in the group with prolonged hospitalization between the groups. In univariate analyzes, it was determined that the presence of Diabetes Mellitus and MHR increased the risk of prolonged hospitalization by 5.25 times and 1.085 times, respectively. In the multivariate analysis of these two parameters, MHR was found to be an independent risk factor for prolonged hospitalization. It was concluded that monocyte/HDL can be used as a simple and reliable parameter to predict the duration of hospitalization in patients with mild acute pancreatitis.

1 September 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MDMustafa Duran
Mustafa Duran
NBNermin Keni Begendi
Nermin Keni Begendi
Purpose: This study aimed to evaluate whether integrating the CRP/Albumin Ratio (CAR) and Lactate Dehydrogenase (LDH) levels into the Modified Glasgow Prognostic Score (mGPS) enhances its prognostic accuracy in patients with multiple myeloma (MM). Patients and Methods: A single-center retrospective study was conducted on patients diagnosed with multiple myeloma (MM) at Afyonkarahisar Health Sciences University between 2017 and 2023. Demographic, clinical, and laboratory data including mGPS, CAR, LDH, and ISS staging were collected. Survival outcomes were assessed using Kaplan-Meier curves, and Cox regression models were used to determine prognostic factors. Results: Among the 130 patients, the ISS score was the strongest predictor of mortality (HR = 1.63, 95% CI: 1.27– 2.09, p = 0.0001). mGPS 2 combined with LDH > 250 IU (HR = 1.96, 95% CI: 1.32– 2.92) and CAR > 0.51 (HR = 1.71, 95% CI: 1.16– 2.53) were independent risk factors. mGPS alone remained a consistent prognostic marker (HR = 1.42, 95% CI: 1.14– 1.77). One-year survival was 50.0% in the mGPS 2 group, dropping to 30.3% at two years. The mGPS 2 + LDH > 250 IU group had the poorest survival (39.5% to 23.3%), followed by the mGPS 2 + CAR > 0.51 group (44.9% to 28.6%). Median PFS was 28.0, 47.0, and 9.0 months in mGPS0, mGPS1, and mGPS2, respectively (p < 0.001), with mGPS2 showing significantly shorter PFS. mGPS2, CAR, LDH, and their combinations were independent predictors of progression. In mGPS2, OS and PFS declined steadily over 36 months, with the lowest long term PFS in the CAR elevated subgroup. Conclusion: Integrating CAR and LDH into the mGPS offers a cost-effective and accessible approach to improve risk stratification in patients with MM. This enhanced model provides a comprehensive assessment of systemic inflammation and tumour burden, supporting its potential use in clinical decision making.

1 November 2024
Verified
Book
Open access
PDF file
İKİbrahim Keleş
İbrahim Keleş
AGAbdullah Gürel
Abdullah Gürel
VYVeli mert Yazar
Veli mert Yazar
MDMustafa Duran
Mustafa Duran
MSMehmet Enes Süzek
Mehmet Enes Süzek
MIMustafa Esat İnce
Mustafa Esat İnce
Kan Pıhtılaşma Mekanizması Mustafa DURAN Mehmet Enes SÜZEK Antikoagulan Ve Antiagregan İlaçların Tarihsel Gelişimi ve Etki Mekanizmaları Mustafa DURAN Pirsu UĞUZ Yeni Kuşak Antikoagülan ve Antiagregan İlaçlar ve Etki Mekanizmaları Haşmet SARICI Recep UZUN Antikoagülan ve Antiagregan İlaçların Genel Kullanım Endikasyonları Hayri DEMİRBAŞ Sinem YORGANCI Antikoagülan ve Antiagregan İlaçların Genel Komplikasyonları Ramazan GENCAN Abdullah GÜREL Antikoagülan ve Antiagregan İlaç Kullanan Hastaları Hangi Parametrelerle Takip Ediyoruz? Serkan GÖKASLAN Antiagregan İlaç Kullanan Hastalarda Sistoskopi ve Sistostomi Operasyonu: Hasta Hazırlık ve Takip Süreci Kutay TOPAL Kemal ULUSOY Antikoagülan-Antiagrean Kullanan Hastalarda Perkutan Nefrostomi Takılması; Preop Hasta Hazırlığı ve Hasta Takip Süreci Çiğdem ÖZER GÖKASLAN Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Temiz Aralıklı Kateterizasyon Kullanımı Ersin BEŞTAŞ Ümit DÜNDAR Antikogülan ve Antiagregan İlaç Kullanan Hastalarda Prostat Biyopsi İşlemi: Preop Hasta Hazırlık ve Postop Takip Süreci Veli Mert YAZAR Murat Cengizhan ATİK Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Transüretral Prostat Rezeksiyonu Operasyonu: Preoperatif Hasta Hazırlık ve Postoperatif Takip Süreci Demirhan Örsan DEMİR Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Holmium Laser Prostatektomi: Preop Hasta Hazırlık ve Postop Takip Süreci Arif DEMİRBAŞ Berkay EREN Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Tur-M Operasyonu: Preop Hasta Hazırlık ve Postop Takip Süreci Osman GERÇEK Melih ŞENKOL Antiagregan İlaç Kullanan Hastalarda Üreteroneskopi ve Retrograd İntrarenal Cerrahi Mustafa KARALAR Muhammed Ali ULUCAK Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Perkütan Nefrolitotomi (PNL) Operasyonu; Preop Hasta Hazırlıkve Postop Takip Süreci Turgay KAÇAN Antikoagülan Ve Antiagregan İlaç Kullanan Hastalarda Radikal Sistektomi ve Radikal Prostatektomi Operasyonu: Preop Hasta Hazırlık ve Postop Takip Süreci Ali Kaan YILDIZ Çoklu Antikoagülan ve Antiagregan Kullanan Koroner Stentli Hastalarda Ürolojik Operasyonların Genel Yönetimi Yusuf TAŞKIN Antikoagülan ve Antiagregan İlaç Kullanan Üroloji Hastalarında Anestezi Yönetimi Bilal Atilla BEZEN Antikoagülan ve Antitrombositik İlaç Kullanan Serebrovasküler Olay Yaşamış Hastalarda Ürolojik Operasyonların Yönetimi Abdullah GÜZEL Hilal Tuğba HOŞGELDİ Antikoagülan Antiagregan İlaç Kullanan ve Abdominopelvik Cerrahi Geçiren Üroloji Hastalarında Pulmoner Komplikasyonların Yönetimi Aydın BALCI Yeni Kuşak Antikoagülan ve Antiagreganların Komplikasyonlarının Vaka Sunumlarıyla İncelenmesi Mustafa Esat İNCE İbrahim KELEŞ

1 November 2024
Verified
Book Chapter
Closed access
MDMustafa Duran
Mustafa Duran
MSMehmet Enes Süzek
Mehmet Enes Süzek
Bu bölüm, kan pıhtılaşma mekanizmasının ürolojik girişimler sırasında antikoagülan ve antiagregan ilaçlar kullanan hastaların yönetimindeki önemini ele almaktadır. Kan pıhtılaşması, kan kaybını önlemek için vücudun geliştirdiği karmaşık bir süreçtir ve hemostazın ana bileşenidir. Süreç, prokoagülanların aktivasyonu, protrombinin trombine dönüşümü ve fibrinojenin fibrin ipliklerine dönüşümü olmak üzere üç ana aşamadan oluşur. Her aşama, pıhtılaşma faktörleri, enzimler ve hücresel bileşenlerin hassas bir etkileşimini içerir. Bu mekanizmaların doğru anlaşılması, ürolojik girişimlerin başarısı ve hastaların güvenliği açısından kritik öneme sahiptir. This section discusses the importance of the blood coagulation mechanism in managing patients using anticoagulant and antiplatelet drugs during urological procedures. Blood coagulation is a complex process developed by the body to prevent blood loss and is a key component of hemostasis. The process involves three main stages: activation of procoagulants, conversion of prothrombin to thrombin, and transformation of fibrinogen into fibrin threads. Each stage involves the precise interaction of clotting factors, enzymes, and cellular components. A thorough understanding of these mechanisms is crucial for the success of urological interventions and patient safety.

1 November 2024
Verified
Book Chapter
Closed access
MDMustafa Duran
Mustafa Duran
PUPirsu Uğuz
Pirsu Uğuz
Antiagregan ve antikoagülan ajanlar, 1930'lardan beri tıbbi tedavide önemli bir yer tutmaktadır. 1916'da unfraksiyone heparinin keşfi ile başlayan süreç, günümüzde yeni nesil oral antikoagülanların da kullanılmasıyla, trombotik olayların tedavisi ve önlenmesinde kritik bir rol oynamaktadır. Antikoagülanlar, venöz tromboembolide hem tedavi hem de profilaksi amacıyla kullanılırken, antiagreganlar daha çok vasküler hastalıkların sekonder korunmasında kullanılır. Heparin, varfarin ve yeni nesil oral antikoagülanlar gibi çeşitli ilaçlar, farklı etki mekanizmalarıyla tromboz riskini azaltmak için kullanılır. Özellikle yeni nesil oral antikoagülanların kullanım kolaylığı ve monitörizasyon gerektirmemesi, bu ilaçların tercih edilmesini sağlamaktadır. Bu ajanların etkin ve güvenli kullanımı, hastaların tedavi süreçlerinde önemli bir yer tutmaktadır.